



Philippines: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility

Project Name	Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility									
Project Number	54171-003									
Country	Philippines									
Project Status	Approved									
Project Type / Modality of Assistance	Loan									
Source of Funding / Amount	<table border="1"> <tr> <td colspan="2">Loan 4050-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility</td> </tr> <tr> <td>Ordinary capital resources</td> <td>US\$ 400.00 million</td> </tr> <tr> <td colspan="2">Loan 8394-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility</td> </tr> <tr> <td>Asian Infrastructure Investment Bank</td> <td>US\$ 300.00 million</td> </tr> </table>		Loan 4050-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility		Ordinary capital resources	US\$ 400.00 million	Loan 8394-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility		Asian Infrastructure Investment Bank	US\$ 300.00 million
Loan 4050-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility										
Ordinary capital resources	US\$ 400.00 million									
Loan 8394-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility										
Asian Infrastructure Investment Bank	US\$ 300.00 million									
Strategic Agendas	Inclusive economic growth Regional integration									
Drivers of Change	Partnerships									
Sector / Subsector	Health - Disease control of communicable disease									
Gender Equity and Mainstreaming	Effective gender mainstreaming									
Description	<p>The proposed loan to the Republic of the Philippines for the Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility (HEAL 2). Under the rapid response component (RRC) of the Asia Pacific Vaccine Access Facility (APVAX), will provide the Government of the Philippines with timely financing for safe and effective vaccine procurement and logistics, based on an agreed list of eligible expenditures. It will supplement the initial support of the Asian Development Bank (ADB) to the government's coronavirus disease (COVID-19) response under the Health System Enhancement to Address and Limit COVID-19 (HEAL) project. HEAL 2 is aligned with three operational priorities of ADB's Strategy 2030: (i) addressing remaining poverty and reducing inequalities; (ii) accelerating progress in gender equality; and (iii) fostering regional cooperation and integration.</p> <p>The Philippines has met all APVAX access criteria by (i) demonstrating the adverse impact of the COVID-19 pandemic; (ii) completing a needs assessment and a vaccination allocation and prioritization plan, including an incremental medical waste management plan and procurement arrangements acceptable to ADB, with ADB's receipt of a Governor's letter confirming its commitment to implement the plan and ensure compliance with the APVAX vaccine eligibility criteria; and (iii) establishing an effective development partner coordination mechanism with a clear role for ADB</p>									
Project Rationale and Linkage to Country/Regional Strategy	<p>Status of the pandemic in the Philippines. The Philippines recorded its first case of COVID-19 on 30 January 2020, and the first case of local transmission on 7 March 2020. Given the threat of COVID-19 to national security, a State of Public Health Emergency was declared on 8 March 2020 through Proclamation No. 922, and the National Capital Region was placed under general community quarantine on 15 March 2020. This was escalated to an enhanced community quarantine for the whole of Luzon on 16 March 2020 to mitigate the spread of the virus. On 16 May 2020, the government started to relax the quarantines and the associated nonpharmaceutical interventions (NPIs) because of the observed stabilization of the number of new cases. However, new cases started to rapidly emerge again by July 2020.</p> <p>The rapid surge prompted a re-imposition of stricter quarantine measures and NPIs by August 2020. As a result, the weekly increases in new COVID-19 cases were reduced from a peak of 23,019 during 6-12 August 2020 to 9,203 during 17-23 December 2020. The daily positivity rate the share of individuals tested and confirmed positive in the total number of individuals tested dropped from 12.7% on 1 August 2020 to 6.5% on 29 December 2020. Although the NPIs are driving down the number of cases, the risk of rapid spikes in new cases, similar to those in July 2020, remains. The new coronavirus variants, which have been observed to be more contagious, add to this risk. The introduction of COVID-19 vaccination is highly critical to lowering the number of new cases and bringing an end to the pandemic.</p>									
Impact	<p>Health system performance in addressing public health outbreaks improved Protection of the public and reduction of COVID-19-related morbidity and mortality fostered Economic growth and citizens' confidence restored</p>									
Project Outcome										
Description of Outcome	Priority populations vaccinated against COVID-19									
Progress Toward Outcome										
Implementation Progress										
Description of Project Outputs	COVID-19 vaccines efficiently and effectively delivered									
Status of Implementation Progress (Outputs, Activities, and Issues)										
Geographical Location	Nation-wide									
Safeguard Categories										
Environment	C									

Involuntary Resettlement	C
Indigenous Peoples	C

Summary of Environmental and Social Aspects	
Environmental Aspects	
Involuntary Resettlement	
Indigenous Peoples	
Stakeholder Communication, Participation, and Consultation	
During Project Design	
During Project Implementation	
Responsible ADB Officer	Tanaka, Sakiko
Responsible ADB Department	Southeast Asia Department
Responsible ADB Division	Human and Social Development Division, SERD
Executing Agencies	Department of Health Tayuman Street Sta. Cruz, Manila Philippines

Timetable	
Concept Clearance	-
Fact Finding	14 Jan 2021 to 14 Jan 2021
MRM	08 Feb 2021
Approval	11 Mar 2021
Last Review Mission	-
Last PDS Update	11 Mar 2021

Loan 4050-PHI

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	464.17	Cumulative Contract Awards			
ADB	400.00	-	0.00	0.00	%
Counterpart	64.17	Cumulative Disbursements			
Cofinancing	0.00	-	0.00	0.00	%

Loan 8394-PHI

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	300.00	Cumulative Contract Awards			
ADB	0.00	-	0.00	0.00	%
Counterpart	0.00	Cumulative Disbursements			
Cofinancing	300.00	-	0.00	0.00	%

Project Page	https://www.adb.org/projects/54171-003/main
Request for Information	http://www.adb.org/forms/request-information-form?subject=54171-003
Date Generated	13 March 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.